Figure 1.
Genetic alterations of PARP1 and its association with TMB level. Prevalence of PARP1 alterations in variety of tumor types (A); Co-occurrence of genetic mutations in tumors with PARP1 alterations (B); The association between TMB and PARP1 alterations in MSK-IMPACT cohort (C), immune checkpoint inhibitors treatment cohort (D), and microsatellite-stable solid tumors received immune checkpoint inhibitors treatment (E); The association between MSI status and PARP1 alternations in TCGA pan-caner cohorts (F).